What the filer says it intends
On the purpose of the transaction, the filing says: “AVF X, AVF X Overage, AVF XIV and the other Reporting Persons acquired the Common Stock for investment purposes. Depending on market conditions, the continuing evaluation of the business and prospects of the Issuer and other factors, AVF X, AVF X Overage, AVF XIV and other Reporting Persons may dispose …” (SEC EDGAR, SCHEDULE 13D, Nov 9, 2026)
The stock
The Nasdaq screener puts its market value at $395.8M. (Nasdaq stock screener, Nov 13, 2026)
Frazier Life Sciences X, L.P. passes 5.0% of Aspen Neuroscience Inc.
In a Schedule 13G filed Nov 9, 2026, Frazier Life Sciences X, L.P. reported 1.7 million shares of Aspen Neuroscience Inc. (ASPE) as of Nov 2, 2026, 5.8% of the class. (SEC EDGAR, SCHEDULE 13G, Nov 9, 2026)
Follow it up
The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/ASPE)
The filing on SEC EDGAR. (sec.gov)
The filing in the MarginsX reader. (MarginsX reader)
Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.
